Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233311 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2 | |
| SCHEMBL4484779 | 0.92 | CXCR2 (0.88) | CX3CR1CXCR2 | |
| SCHEMBL5233725 | 0.91 | CX3CR1 (0.84) | CX3CR1CXCR2 | |
| SCHEMBL5233712 | 0.91 | CX3CR1 (0.84) | CX3CR1CXCR2 | |
| SCHEMBL18312611 | 0.90 | CX3CR1 (0.83) | CX3CR1CXCR2 | |
| SCHEMBL5232254 | 0.90 | CX3CR1 (1.00) | CX3CR1CXCR2 | |
| SCHEMBL20455488 | 0.90 | CX3CR1 (0.83) | CX3CR1CXCR2 | |
| SCHEMBL5232266 | 0.90 | CX3CR1 (1.00) | CX3CR1CXCR2 | |
| SCHEMBL842571 | 0.90 | CXCR2 (1.00) | CX3CR1CXCR2 | |
| SCHEMBL842570 | 0.90 | CXCR2 (1.00) | CX3CR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | claimed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | claimed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-08-09 | — | — | US | disclosed |
| WO-2016200939-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-12-15 | — | — | WO | disclosed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
| EP-1377590-B1 | THIAZOLOPYRIMIDINE DERIVATIVES AND USE THEREOF AS ANTAGONISTS OF THE CX3CR1 RECEPTOR | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | ASTRAZENECA (SE) | 2007-06-21 | — | — | US | disclosed |
| US-7067657-B2 | Thiazolopyrimidine derivatives and use thereof as antagonists of the CX3 CR1 receptor | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | disclosed |
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | disclosed |
| US-20040106628-A1 | Novel use | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | US | disclosed |
| EP-1104425-B1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1104425-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009511-A1 | NOVEL THIAZOLOPYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142386-A1 | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | CX3CR1, CCR2, CXCR4 | CX3CR1 1/4885CXCR2 6/4885 |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 6/4885 |
| US-20180222922-A1 | RADIOFLUORINATED 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES FOR IMAGING FRACTALKINE RECEPTOR (CX3CR1) | CX3CR1, CXCR3, CXCR5 | CX3CR1 1/4885CXCR2 15/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 11/4885 |
| US-20040106628-A1 | Novel use | CX3CR1, CNR1, ARRB1 | CX3CR1 1/4885CXCR2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.